News >

FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 31, 2019

Anne White

Anne White
The FDA has expanded the indication for pemetrexed (Alimta) injection in combination with pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.1

The updated indication is based on data from the phase III KEYNOTE-189 trial, which was the basis for the FDA’s full approval of frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous NSCLC.2,3

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication